PharmAla Receives U.S. Patent, Retains APA-01 Rights And Engages Canaccord Genuity

PharmAla Biotech Holdings announced a U.S. patent grant covering novel enantioselective processes to prepare individual (R)- and (S)-enantiomers of MDMA and MBDB. The company says the grant strengthens its manufacturing capabilities and intellectual property portfolio. Impact is likely limited to incremental reassessment of IP value rather than immediate financial results.

Analysis

PharmAla Biotech Holdings announced a U.S. patent grant covering novel enantioselective processes to prepare individual (R)- and (S)-enantiomers of MDMA and MBDB. The company says the grant strengthens its manufacturing capabilities and intellectual property portfolio. Impact is likely limited to incremental reassessment of IP value rather than immediate financial results.